πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12264366

Genome-based methods for reducing cardiovascular risk

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12266425

T cell receptor sequences diagnostic for COVID-19 and related compositions

Adaptive Biotechnologies Corporation Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264322

Minimal volume reprogramming of mononuclear cells

Fate Therapeutics, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264187

Compositions and methods for targeted therapeutic delivery to bone

Theradaptive, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264336

Platform for generating safe cell therapeutics

The Regents of the University of California Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263145

Methods of administering solriamfetol to lactating women

AXSOME MALTA LTD. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264343

TCRa homing endonuclease variants

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263148

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263139

Use of cannabidiol in the treatment of tuberous sclerosis complex

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264169

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264344

Protein/oligonucleotide core-shell nanoparticle therapeutics

Northwestern University Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263149

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263143

Ionic channel modulation as a method for treating tumors through inflammasome activation

INSTITUT PASTEUR DE MONTEVIDEO Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264158

Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing

HEPAREGENIX GMBH Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264154

Compounds and methods of use

Tango Therapeutics, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264167

Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264149

Indazole compounds as kinase inhibitors

TYRA BIOSCIENCES, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264345

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263156

Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms

The Board of Regents for Oklahoma State University Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263325

Device, system and methods for the oral delivery of therapeutic compounds

Rani Therapeutics, LLC Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263159

Fused ring compound having urea structure

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12258425

Peptide compositions and methods of use

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12258575

RNA-guided nucleic acid modifying enzymes and methods of use thereof

The Regents of the University of California Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12258597

Methods and compositions for therapeutic protein delivery

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted